Consistent with these observations, shRNA targeting CD84 in 2 preleukemic AML mouse cells, MLL-AF9 and inv(16) AML, inhibited cell viability and delayed leukemic onset in recipient mice. Here, KMT2A is linked to acute myeloid leukemia.